101 related articles for article (PubMed ID: 1740697)
1. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.
Okada J; Yoshikawa K; Itami M; Imaseki K; Uno K; Itami J; Kuyama J; Mikata A; Arimizu N
J Nucl Med; 1992 Mar; 33(3):325-9. PubMed ID: 1740697
[TBL] [Abstract][Full Text] [Related]
2. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET for predicting the prognosis of malignant lymphoma.
Okada J; Oonishi H; Yoshikawa K; Itami J; Uno K; Imaseki K; Arimizu N
Ann Nucl Med; 1994 Aug; 8(3):187-91. PubMed ID: 7811561
[TBL] [Abstract][Full Text] [Related]
4. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman JS; Francis IR; Kaminski MS; Wahl RL
Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
[TBL] [Abstract][Full Text] [Related]
5. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
[TBL] [Abstract][Full Text] [Related]
6. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.
Okazumi S; Isono K; Enomoto K; Kikuchi T; Ozaki M; Yamamoto H; Hayashi H; Asano T; Ryu M
J Nucl Med; 1992 Mar; 33(3):333-9. PubMed ID: 1311035
[TBL] [Abstract][Full Text] [Related]
8. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.
Lapela M; Leskinen S; Minn HR; Lindholm P; Klemi PJ; Söderström KO; Bergman J; Haaparanta M; Ruotsalainen U; Solin O; Joensuu H
Blood; 1995 Nov; 86(9):3522-7. PubMed ID: 7579459
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis of glucose metabolism by FDG-PET versus proliferation index of Ki-67 in meningiomas--comparison with gliomas.
Tsuyuguchi N
Osaka City Med J; 1997 Dec; 43(2):209-23. PubMed ID: 9540343
[TBL] [Abstract][Full Text] [Related]
10. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer.
Lindholm P; Leskinen-Kallio S; Minn H; Bergman J; Haaparanta M; Lehikoinen P; Någren K; Ruotsalainen U; Teräs M; Joensuu H
J Nucl Med; 1993 Oct; 34(10):1711-6. PubMed ID: 8410288
[TBL] [Abstract][Full Text] [Related]
12. High [18F]FDG uptake in primary cerebral lymphoma: a PET study.
Kuwabara Y; Ichiya Y; Otsuka M; Miyake Y; Gunasekera R; Hasuo K; Masuda K; Takeshita I; Fukui H
J Comput Assist Tomogr; 1988; 12(1):47-8. PubMed ID: 3257221
[TBL] [Abstract][Full Text] [Related]
13. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
14. A study of vestibular schwannomas using positron emission tomography and monoclonal antibody Ki-67.
Chen JM; Houle S; Ang LC; Commins D; Allan K; Nedzelski J; Rowed D
Am J Otol; 1998 Nov; 19(6):840-5. PubMed ID: 9831165
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
[TBL] [Abstract][Full Text] [Related]
16. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.
Janus TJ; Kim EE; Tilbury R; Bruner JM; Yung WK
Ann Neurol; 1993 May; 33(5):540-8. PubMed ID: 8498831
[TBL] [Abstract][Full Text] [Related]
17. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate.
Kuwabara H; Gjedde A
J Nucl Med; 1991 Apr; 32(4):692-8. PubMed ID: 2013809
[TBL] [Abstract][Full Text] [Related]
18. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
19. [18F-FDG uptake of lymphoma lesions of various histological subtypes].
Ma LF; Fan W
Ai Zheng; 2009 Apr; 28(4):425-30. PubMed ID: 19622306
[TBL] [Abstract][Full Text] [Related]
20. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG).
Hubner KF; McDonald TW; Niethammer JG; Smith GT; Gould HR; Buonocore E
Gynecol Oncol; 1993 Nov; 51(2):197-204. PubMed ID: 8276294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
